Table 1.
Patient, transplant and graft characteristics.
| Recipient | Variable | n |
|---|---|---|
| Age (years) | Median (range) | 48 (18 - 74) |
| Gender | Male / Female | 58 / 36 |
| CMV serology | Negative / Positive | 48 / 46 |
| ABO | O / A / B / AB | 40 / 37 / 8 / 9 |
| Disease | Acute Leukaemia (AML / ALL) | 47 (34 / 13) |
| Other (Lymp / Mye / MDS) | 47 (27 / 10 / 10) | |
| Disease status | Early / Other | 46 / 48 |
| Donor | n | |
|---|---|---|
| Age (years) | Median (range) | 40 (19 - 72) |
| Gender | Male / Female | 64 / 30 |
| CMV serology | Negative / Positive | 64 / 30 |
| ABO | O / A / B / AB | 41 / 45 / 4 / 4 |
| Recipient/Donor | n | |
|---|---|---|
| Gender (R:D) | Male:Female / Other | 17 / 77 |
| CMV matching (R:D) | −/−, −/+, +/−, +/+ | 38 / 10 / 26 / 20 |
| ABO matching | Matched / Minor / Major / Bidirectional | 58 / 18 / 13 / 5 |
| HLA matching | Matched / mM HvG / mM GvH / mM Bi | 77 / 2 / 3 / 12 |
| Transplant | n | |
|---|---|---|
| Donor | Sibling / Unrelated | 38 / 56 |
| Conditioning | Myeloablative (CyTBI / BuCy) | 14 (12 / 2) |
| Reduced intensity (FluMel / FluCy) | 80 (79 / 1) | |
| Graft | PBSC / BM | 94 / 0 |
| Alemtuzumab | No / Yes | 36 / 58 |
| PBSC graft | × 106/kg | |
|---|---|---|
| TNC | Median (range) | 1006 (266 - 3762) |
| CD34+ | Median (range) | 6.3 (1.1 - 19.8) |
| CD3+ | Median (range) | 280 (87 - 801) |
| CD3+CD4+ | Median (range) | 171 (50 - 694) |
| CD3+CD8+ | Median (range) | 82 (26 - 248) |
| CD19+ | Median (range) | 62 (13 - 245) |
| CD3−CD56+ | Median (range) | 35 (8 - 101) |
| Tregs | Median (range) | 4.7 (0.8 - 20.6) |
| Tregs/CD4+ T cells | Median (range) | 0.0296 (0.008 - 0.086) |
Lymp, lymphoproliferative; Mye, myeloproliferative; Early = CR1, 1st chronic phase or untreated; R:D, recipient:donor; mM, mismatched; HvG, host-versus-graft; GvH, graft-versus-host; Bi, bidirectional; CyTBI, Cyclophosphamide/TBI; BuCy, Busulphan/Cyclophosphamide; FluMel, Fludarabine/Melphalan; FluCy, Fludarabine/Cyclophosphamide; TNC, total nucleated cells; Tregs, regulatory T cells.